Monday, January 27, 2020
Monday, January 20, 2020
Longenesis and ATA Club to deploy a blockchain-based consent management tool
The partnership will aim to unlock the for-profit sharing of biomedical data SEOUL, January 13, 2020 — a South Korean athletes association ATA Club Co. and health data company Longenesis signed an agreement to deploy a custom blockchain-based paperless consent management toolkit.
The consent management tool, built on Bitfury’s open-source Exonum blockchain framework, allows convenient and fast paperless consent retrieval, in accordance with all the data privacy regulations, including South Korean data privacy regulation PIPA.
The Longenesis toolkit consisting of the athlete oriented interface for direct and uninterrupted communication with data owners, the consent management tool for permission retrieval and access to the showcase and data querying web platform for anonymized metadata will enable ATA Club not only to communicate, survey and assemble profiles of the members, but also to be able to share these datasets for-profit with stakeholders for their R&D needs.
Garri Zmudze, CEO of Longenesis, notes “This partnership is among the first where a non-healthcare organization is to provide reach to individuals for on-demand data generation to R&D organizations”
The toolkit allows harvesting and streamlining real-world data coming directly from athletes and using this data in the research of sports nutrition and pharma companies. Additionally, the datasets will be supplemented by sequenced genomes, providing more in-depth analysis and data to the datasets. Negotiations with the South Korean genome sequencer to join the project are at the final stage. The solution will provide the R&D stakeholders with direct access to athletes for on-demand data generation and product validation.
About ATA Club Co.
Athletes Association Club is a company revolutionising the sports community market by building a global decentralised sports platform for non-professional athletes. For more information visit: http://ataclub.io
About Longenesis
Longenesis is atechcompany,foundedinlate2017byInsilicoMedicine,apioneerinAIfor drugdiscovery,andtheBitfuryGroup,theleadingfull-serviceblockchaintechnology company.Longenesisistheexclusivehealthcareapplicationproviderforopen-source frameworkExonum™.Longenesisenableshealthcareinstitutionstotransformbiomedical datatheyholdintoshareableassetsandhelpPharmaandCROswithRWD-basedclinical trialrecruitment. Formoreinformationvisit:www.longenesis.com.
The consent management tool, built on Bitfury’s open-source Exonum blockchain framework, allows convenient and fast paperless consent retrieval, in accordance with all the data privacy regulations, including South Korean data privacy regulation PIPA.
The Longenesis toolkit consisting of the athlete oriented interface for direct and uninterrupted communication with data owners, the consent management tool for permission retrieval and access to the showcase and data querying web platform for anonymized metadata will enable ATA Club not only to communicate, survey and assemble profiles of the members, but also to be able to share these datasets for-profit with stakeholders for their R&D needs.
Garri Zmudze, CEO of Longenesis, notes “This partnership is among the first where a non-healthcare organization is to provide reach to individuals for on-demand data generation to R&D organizations”
The toolkit allows harvesting and streamlining real-world data coming directly from athletes and using this data in the research of sports nutrition and pharma companies. Additionally, the datasets will be supplemented by sequenced genomes, providing more in-depth analysis and data to the datasets. Negotiations with the South Korean genome sequencer to join the project are at the final stage. The solution will provide the R&D stakeholders with direct access to athletes for on-demand data generation and product validation.
About ATA Club Co.
Athletes Association Club is a company revolutionising the sports community market by building a global decentralised sports platform for non-professional athletes. For more information visit: http://ataclub.io
About Longenesis
Longenesis is atechcompany,foundedinlate2017byInsilicoMedicine,apioneerinAIfor drugdiscovery,andtheBitfuryGroup,theleadingfull-serviceblockchaintechnology company.Longenesisistheexclusivehealthcareapplicationproviderforopen-source frameworkExonum™.Longenesisenableshealthcareinstitutionstotransformbiomedical datatheyholdintoshareableassetsandhelpPharmaandCROswithRWD-basedclinical trialrecruitment. Formoreinformationvisit:www.longenesis.com.
Longenesis joins forces with Northern European oncologists, academia and female oncology patient association to launch digital pre-screening program for early diagnostics and proactive involvement in breast and cervical cancer-related studies
14th of January 2020, San Francisco, USA
Longenesis, a company based out of Asian and Northern Europe, disrupting an industry for compliant
access to medical data for clinical studies, formed a partnership alliance together with DF LAB
Healthcare Technology Project Laboratory (University of Latvia), VITA female oncology patient
association to launch a digital breast and cervical cancer pre-screening program for early diagnostics and proactive involvement in cancer-related studies in Northern European region.
Partners propose a new model for breast cancer-related risk calculation. It is based on a web interface and involves multiple data types, such as phenotypic metrics (survey results), visual red flags (early breast cancer symptoms), self-examination tool and genotypic data (genotypic result upload form). The model is implemented in a web-based tool where users have the ability to proactively enter the data into the platform and receive a customized report + “how-to” instructions for performing a standard screening in the Baltic region and receiving subsidized ancestor mutations genotypic testing. The model also allows users to provide their digital consent for input data processing and consent for potential participation in follow-on virtual studies, such as additional questionnaires, etc.
As a result, a tool developed by Longenesis will serve to:
- Educate and raise awareness about breast and cervical cancer-related risks;
- Involve patients/users into virtual study onboarding and access to new diagnostics,
assessment and treatment tools;
- correlate multiple data types (genotypic, phenotypic, visual) for risk assessment.
The project currently involves resident doctors, researchers for potential epidemiological studies and aims to reach 15 000 female participants in Q1 2020. The results will be published and showcased to the National Healthcare Service as a novel approach for population-wide cancer risk assessment and
preventive healthcare. The web-based platform will be publically available starting early February 2020.
About Longenesis:
Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Longenesis is the exclusive healthcare application provider for open-source framework ExonumTM. The main goal of the company is to disrupt an industry for compliant access to medical data for clinical studies with a set of technological tools developed for pharma, clinics, researchers, data analytics companies, and patients’ proactive involvement in clinical and research studies, generating prospective biomedical data for insights generation.
Longenesis, a company based out of Asian and Northern Europe, disrupting an industry for compliant
access to medical data for clinical studies, formed a partnership alliance together with DF LAB
Healthcare Technology Project Laboratory (University of Latvia), VITA female oncology patient
association to launch a digital breast and cervical cancer pre-screening program for early diagnostics and proactive involvement in cancer-related studies in Northern European region.
Partners propose a new model for breast cancer-related risk calculation. It is based on a web interface and involves multiple data types, such as phenotypic metrics (survey results), visual red flags (early breast cancer symptoms), self-examination tool and genotypic data (genotypic result upload form). The model is implemented in a web-based tool where users have the ability to proactively enter the data into the platform and receive a customized report + “how-to” instructions for performing a standard screening in the Baltic region and receiving subsidized ancestor mutations genotypic testing. The model also allows users to provide their digital consent for input data processing and consent for potential participation in follow-on virtual studies, such as additional questionnaires, etc.
As a result, a tool developed by Longenesis will serve to:
- Educate and raise awareness about breast and cervical cancer-related risks;
- Involve patients/users into virtual study onboarding and access to new diagnostics,
assessment and treatment tools;
- correlate multiple data types (genotypic, phenotypic, visual) for risk assessment.
The project currently involves resident doctors, researchers for potential epidemiological studies and aims to reach 15 000 female participants in Q1 2020. The results will be published and showcased to the National Healthcare Service as a novel approach for population-wide cancer risk assessment and
preventive healthcare. The web-based platform will be publically available starting early February 2020.
About Longenesis:
Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Longenesis is the exclusive healthcare application provider for open-source framework ExonumTM. The main goal of the company is to disrupt an industry for compliant access to medical data for clinical studies with a set of technological tools developed for pharma, clinics, researchers, data analytics companies, and patients’ proactive involvement in clinical and research studies, generating prospective biomedical data for insights generation.
Tuesday, January 14, 2020
Insilico collaborates with Pfizer on novel data and AI system for target discovery
Tuesday, 14th of January, 2020 (8:00 AM New York) - Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.
"Insilico is advancing its latest target identification systems utilizing machine learning, generative biology methods, and synthetic data generation pipelines, and we are pleased to be collaborating with Pfizer on its target identification efforts," said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine.
"We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs," said Morten Sogaard, Vice President, Target Sciences, Pfizer.
In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors.
###
About Insilico Medicine
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine published some of the results in Nature Biotechnologyand secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 70 peer-reviewed papers, applied for over 20 patents, and received multiple industry awards.
Website http://insilico.
Media Contact
For further information, images, or interviews, please contact:
ai@insilico.com
ai@insilico.com
Friday, January 10, 2020
Insilico Medicine to present new results in generative biology AI
Friday, January 10, 2020 - Insilico Medicine, a biotechnology company developing end-to-end drug discovery pipelines utilizing the next-generation artificial intelligence, to present new results of its generative biology pipeline resulting in novel targets in liver disease.
The company will showcase the results of the first experimental validation of its generative biology target ID system at CTIC on the 12th of January, 2020 and at Biotech Showcase, 13th of January, 2020.
"For the first time, we will present the results of our generative biology pipeline resulting in novel targets for liver disease during the JP Morgan. This is a major milestone for us, and we are happy to continue making history in AI-powered biomedicine," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
You can also meet Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine at FierceBiotech Executive Breakfast on the 14th of January, 2020.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe ai@pharma.ai
About Insilico Medicine
Insilico Medicine is an artificial intelligence company with offices in six countries and regions striving to accelerate three areas of drug discovery and development: disease target identification, generation of novel molecules (generative chemistry) and synthetic biological data (generative biology), and prediction of clinical trial outcomes. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas. Recently, Insilico Medicine published a proof-of-concept study in generative chemistry in Nature Biotechnology, and secured $37 million in series B funding.
Website http://insilico.
Thursday, January 9, 2020
Beiersdorf and Insilico employ AI technology in computer-simulated skin research
- Beiersdorf uses artificial intelligence to accelerate the discovery of novel and safe active ingredients
- New molecules for a specific skin indication to be generated and analyzed using next-generation artificial intelligence developed by Insilico Medicine
- Beiersdorf is a leader in the development and application of novel AI technologies to skincare and is collaborating with an ecosystem of startup companies
Hamburg, January 8, 2020 - Beiersdorf and Insilico Medicine, an artificial intelligence company developing end to end drug discovery pipelines, announced today that they are entering a collaboration to jointly discover novel, safe bioactive ingredients for a specific skin indication at an unparalleled pace, that will serve as the basis for developing appropriate skincare products.
"As part of our Open Innovation culture, we are always looking for new technologies and partners with strengths that complement ours. We are delighted to now be working with Insilico Medicine as a veritable expert when it comes to artificial intelligence. We are able to evaluate new active ingredients significantly more quickly and more efficiently by simulating biological effects in silico. This enables us to cater even better to the consumers' as yet unmet skincare needs," explains Dr. May Shana'a, Senior Corporate Vice President, Research and Development, at Beiersdorf.
Alex Zhavoronkov, CEO of Insilico Medicine, is likewise excited about the joint effort: "We firmly believe there is a great potential in this collaboration. We worked with many consumer companies in the past and in my opinion, Beiersdorf became an undisputed leader in the area of skin research as well as in digital technologies in recent decades. We are delighted that they have recognized the potential of artificial intelligence early on and hope to demonstrate the power of AI going forward in our collaboration."
###
About Insilico Medicine
Insilico Medicine is an artificial intelligence company with offices in six countries and regions striving to accelerate three areas of drug discovery and development: disease target identification, generation of novel molecules (generative chemistry) and synthetic biological data (generative biology), and prediction of clinical trial outcomes. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas. Recently, Insilico Medicine published a proof-of-concept study in generative chemistry in Nature Biotechnology, and secured $37 million in series B funding.
Website: http://insilico.
About Beiersdorf AG
Beiersdorf AG is a leading provider of innovative, high-quality skincare products and has over 135 years of experience in this market segment. The Hamburg-based company has approximately 20,000 employees worldwide and is listed on the DAX, the German benchmark equities index. Beiersdorf generated sales of more than 7.2 billion euros in fiscal year 2018. The Beiersdorf product portfolio is characterized by strong, globally leading skincare and personal care brands such as the world's number one skincare brand NIVEA, Eucerin, Hansaplast, and La Prairie. They impress millions of people around the world every day with their innovative and high-quality products. The extensive portfolio is complemented by other renowned brands like Labello, Aquaphor, Florena, 8X4, Hidrofugal, atrix, Maestro, and Coppertone. Beiersdorf's wholly owned affiliate tesa SE, another globally leading manufacturer in its field, supplies self-adhesive products and system solutions to industry, craft businesses, and consumers.
Source: Euromonitor International Limited; NIVEA as umbrella brand in the categories Face Care, Body Care, and Hand Care; in retail value terms, 2018.
Contact:
Subscribe to:
Posts (Atom)